An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma

Endocrine Pathology

Volumn 20, Issue 1, 2009, Pages 17-23

  Nakamura, Megumi ^a   Miki, Yasuhiro ^a   Akahira, Jun Ichi ^a   Morimoto, Ryo ^a   Satoh, Fumitoshi ^a   Ishidoya, Shigeto ^a   Arai, Yoichi ^a   Suzuki, Takashi ^b   Hayashi, Yutaka ^a   Sasano, Hironobu ^a,c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adrenocortical carcinoma; EGFR; Immunohistochemistry; PI3K Akt pathway; Ras ERK pathway; Target specific therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; RAS PROTEIN; S6 KINASE; VASCULOTROPIN A; TUMOR MARKER;

ADOLESCENT; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADRENAL CORTEX TUMOR; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; CHILD; CHILD, PRESCHOOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 66349120812     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9058-2     Document Type: Article

References (37)

1. Rescorla FJ. Malignant adrenal tumors. Semin Pediatr Surg 15:48-56, 2006. doi:10.1053/j.sempedsurg.2005.11.008. (Pubitemid 43177162)
2. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380, 2007. doi:10.1056/ NEJMoa063360. (Pubitemid 46883771)
3. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153-163, 2007. doi:10.1186/1471-2407-7-153. (Pubitemid 47354734)
4. Thatcher N. The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer 57 (Suppl 2):S18-23.11, 2007.
5. Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42:290-294, 2006. doi:10.1016/j.ejca.2005.07.034. (Pubitemid 43132883)
6. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 64:2045-2075, 2007.
7. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169, 1984. doi:10.1097/00000478-198403000-00001.
8. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol 17:345-354, 2006. doi:10.1007/s12022-006-0006-0. (Pubitemid 47012402)
9. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000. doi:10.1093/emboj/19.13.3159.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9:669-676, 2003. doi:10.1038/nm0603-669. (Pubitemid 36749215)
11. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signaling in cancer: from expression to turnover. Biochem Biophys Acta 1766:120-139, 2006.
12. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:6577-6592, 2007. doi:10.1038/sj.onc.1210478. (Pubitemid 47573679)
13. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62:179-213, 2007. doi:10.1016/j. critrevonc.2007.01.006. (Pubitemid 46679285)
14. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263, 2002. doi:10.1038/sj.onc.1205794.
15. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317-1323, 2005. doi:10.1056/NEJMoa042831. (Pubitemid 40411498)
16. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006. doi:10.1038/sj. bjc.6603419.
17. Pearson G, Robinson F, Beers GT, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183, 2001. doi:10.1210/er.22.2.153. (Pubitemid 32458157)
18. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signaling: AKTion on multiple fronts. Trends Biochem Sci 29:233-242, 2004. doi:10.1016/j.tibs.2004.03.006. (Pubitemid 38591317)
19. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807-826, 2001. doi:10.1101/ gad.887201.
20. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 25:6416-6422, 2006. doi:10.1038/sj.onc.1209888. (Pubitemid 44582285)
21. Kaio E, Tanaka S, Kitadai Y, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 64:61-73, 2003. doi:10.1159/000066511. (Pubitemid 35477956)
22. Derecskei K, Moldvay J, Bogos K, Tímár J. Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues. Pathol Oncol Res 12:243-246, 2006.
23. Yamashita S, Suzuki S, Nomoto T, et al. Linkage and microarray analyses of susceptibility genes in ACI/Seg rats: a model for prostate cancers in the aged. Cancer Res 65:2610-2616, 2005. doi:10.1158/0008-5472.CAN-04-2932. (Pubitemid 40490059)
24. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phosphor-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171, 2002.
25. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177:346-352, 2007. doi:10.1016/j.juro.2006. 08.076.
26. Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J. PDK-1/ AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 97:785-791, 2007. doi:10.1038/sj.bjc.6603952. (Pubitemid 47396297)
27. Miyata H, Chiang AC, Vinters HV. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann Neurol 56:510-519, 2004. doi:10.1002/ana.20234. (Pubitemid 39319341)
28. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 272:4211-4220, 2005. doi:10.1111/j.1742-4658. 2005.04833.x. (Pubitemid 41160927)
29. Sasano H, Suzuki T, Shizawa S, Kato K, Nagura H. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol 7:741-746, 1994.
30. Loprevite M, Tiseo M, Chiaramondia M, et al. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. Clin Cancer Res 13:6518-6526, 2007. doi:10.1158/1078-0432.CCR- 07-0805. (Pubitemid 350075043)
31. Yashiro T, Hara H, Fulton NC, Obara T, Kaplan EL. Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World J Surg 18:455-461, 1994. doi:10.1007/BF00353735.
32. Lin SR, Tsai JH, Yang YC, Lee SC. Mutation of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 77:1060-1065, 1998.
33. Zacharieva S, Atanassova I, Orbetzova M, et al. Circulating vascular endothelial growth factor and active rennin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumors. Eur J Endocrinol 150:345-349, 2004. doi:10.1530/ eje.0.1500345.
34. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproreomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 36:283-293, 2006.
35. Molinolo AA, Heiwitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964-73, 2007. doi:10.1158/1078- 0432.CCR-07-1041.
36. Pérez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13:3577-3584, 2007. doi:10.1158/1078-0432.CCR-06-1609. (Pubitemid 46955118)
37. Schmitz KJ, Wohlschlaeger J, Alakus H, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with kras mutations. Virchows Arch 450:151-159, 2007. doi:10.1007/ s00428-006-0342-y.